Abstract
DNA methylation is an epigenetic phenomenon, which has major effects on gene expression. Increased methylation generally inhibits transcription while hypomethylation is primarily associated with increased transcription. Hypermethylation of tumor suppressor genes occurs frequently in cancer leading to silencing of these growth inhibitory genes. Demethylating agents are a class of anti-cancer drugs which reduce cytosine methylation, promoting transcriptional activation of genes by virtue of reducing methylation in their promoter regions. Most compounds that inhibit methylation are inhibitors of DNA methyltransferases (DNMTs) that are responsible for methylating cytosine residues on DNA. Azacitidine and Decitabine are two such demethylating agents that are approved for use in myelodysplastic syndromes. In this review, we describe the pharmacology of demethylating agents and their use in recent clinical studies. The current literature describing the efficacy of combining these agents with other chemotherapeutics in various types of cancer is also reviewed.
Keywords: Cancer, Demethyating Agents, DNA Methylation, Epigenetics.
Current Cancer Therapy Reviews
Title:Demethylating Agents as Epigenetic Anticancer Therapeutics
Volume: 9 Issue: 1
Author(s): Arash Nabbi, Shankha Satpathy and Karl Riabowol
Affiliation:
Keywords: Cancer, Demethyating Agents, DNA Methylation, Epigenetics.
Abstract: DNA methylation is an epigenetic phenomenon, which has major effects on gene expression. Increased methylation generally inhibits transcription while hypomethylation is primarily associated with increased transcription. Hypermethylation of tumor suppressor genes occurs frequently in cancer leading to silencing of these growth inhibitory genes. Demethylating agents are a class of anti-cancer drugs which reduce cytosine methylation, promoting transcriptional activation of genes by virtue of reducing methylation in their promoter regions. Most compounds that inhibit methylation are inhibitors of DNA methyltransferases (DNMTs) that are responsible for methylating cytosine residues on DNA. Azacitidine and Decitabine are two such demethylating agents that are approved for use in myelodysplastic syndromes. In this review, we describe the pharmacology of demethylating agents and their use in recent clinical studies. The current literature describing the efficacy of combining these agents with other chemotherapeutics in various types of cancer is also reviewed.
Export Options
About this article
Cite this article as:
Nabbi Arash, Satpathy Shankha and Riabowol Karl, Demethylating Agents as Epigenetic Anticancer Therapeutics, Current Cancer Therapy Reviews 2013; 9 (1) . https://dx.doi.org/10.2174/1573394711309010003
DOI https://dx.doi.org/10.2174/1573394711309010003 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on Biotechnology Discovery of New Biomarkers of Cancer Using Proteomics Technology
Current Cancer Therapy Reviews Review of Airway Illnesses by Kytococcus and Rothia and a Look at Inhalatory Vancomycin as a Treatment Support
Recent Patents on Anti-Infective Drug Discovery Targets for Steroid Hormone Mediated Actions of Periodontal Pathogens, Cytokines and Therapeutic Agents Some Implications on Tissue Turnover in the Periodontium
Current Drug Targets Chemical Synthesis, Characterisation and Biological Evaluation of Furanic- Estradiol Derivatives as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
Medicinal Chemistry A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Advances in Computational Structure-Based Drug Design and Application in Drug Discovery
Current Topics in Medicinal Chemistry Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets New Perspectives in the Treatment of Melanoma: Anti-Angiogenic and Anti-Lymphangiogenic Strategies
Recent Patents on Anti-Cancer Drug Discovery Stem Cells: An Overview of the Current Status of Therapies for Central and Peripheral Nervous System Diseases
Current Medicinal Chemistry Synthesis and Ultraviolet Absorption Characteristics of Chiral 3- arylidenenopinones from β-pinene
Letters in Drug Design & Discovery Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics Pharmacogenetic Variation and Metformin Response
Current Drug Metabolism Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry Future Challenges for Microsomal Transport Protein Inhibitors
Current Vascular Pharmacology Mesenchymal Stem Cells, Immune Cells and Tumor Cells Crosstalk: A Sinister Triangle in the Tumor Microenvironment
Current Stem Cell Research & Therapy New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience Performance of Feature Selection Methods
Current Genomics